21st Oct 2008 09:00
Stock Exchange announcement
Tuesday 21 October 2008
CELSIS INTERNATIONAL PLC
NOTIFICATION OF RESULTS
21 October 2008: Celsis International plc, the life sciences products and laboratory services company, will announce its interim results for the six months ended 30 September 2008 on Wednesday 12 November 2008.
There will be a presentation to analysts on the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB. There will also be a conference call available, for more information please contact Juliet Edwards on +44 (0)207 269 7125.
|
Enquiries: |
|
|
Celsis International plc |
Tel: 01223 598 428 |
|
Jay LeCoque, Chief Executive Officer |
|
|
Robyn LaLonde, Executive Assistant to CEO |
|
|
Financial Dynamics |
Tel: 020 7831 3113 |
|
David Yates |
|
|
Jonathan Birt |
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.
Related Shares:
Celadon Pharmaceuticals